Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
Generic APIs at Crossroads - 2: Traders’ Group Urges Simpler Regulatory Procedures to Facilitate API Substitution
Ichiro Fujikawa, chairman of the Japan Pharmaceutical Traders’ Association (JPTA), an organization of importers of APIs and intermediates, calls on the government to simplify regulatory procedures to make it easier for companies to switch to substitute APIs if the COVID-19…
To read the full story
Related Article
- Generic APIs at Crossroads - 4: Professor Calls for Monitoring Drugs Liable to Be in Short Supply, Drawing Up Lists of Substitutes
August 17, 2020
- Generic APIs at Crossroads - 3: Gx Society Sets Up Committee for Discussions with Healthcare Providers and API Manufacturers
August 14, 2020
- Generic APIs at Crossroads - 1: Sawai Quality Chief Says Current Biz Structure Hampers Manufacturing Repatriation
July 29, 2020
ORGANIZATION
- New Chuikyo Pharmacist Rep Urges 2027 Revision to Stay within 4-Minister Deal
August 3, 2026
- Ectopic Fat Research Group Launches to Push Cross-Disciplinary Studies
July 31, 2026
- JPMA Chief Seeks Concrete Reforms to Reward Innovation after Honebuto
July 31, 2026
- Patient Groups Launch Consortium to Improve Access to Drug Information
July 31, 2026
- Radiopharma Group Seeks Faster NHI Coverage for PET Imaging Agents
July 28, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…